{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:38:02Z","timestamp":1788223082376,"version":"build-2803163510"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","award":["19\/06"],"award-info":[{"award-number":["19\/06"]}],"id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0223464","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T13:28:35Z","timestamp":1588858115000},"page":"e0223464","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding"],"prefix":"10.1371","volume":"15","author":[{"given":"Rumbidzai","family":"Chitongo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetayo Emmanuel","family":"Obasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sello Given","family":"Mikasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3259-1496","authenticated-orcid":true,"given":"Graeme Brendon","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-0212","authenticated-orcid":true,"given":"Ruben","family":"Cloete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,5,7]]},"reference":[{"issue":"3","key":"pone.0223464.ref001","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrd1660","article-title":"Integrase inhibitors to treat HIV\/AIDS","volume":"4","author":"Y Pommier","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"pone.0223464.ref002","doi-asserted-by":"crossref","first-page":"13659","DOI":"10.1073\/pnas.93.24.13659","article-title":"Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity","volume":"93","author":"R Zheng","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"pone.0223464.ref003","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1021\/jm800245z","article-title":"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection","volume":"51","author":"V Summa","year":"2008","journal-title":"J Med Chem"},{"key":"pone.0223464.ref004","first-page":"81","article-title":"Role of raltegravir in the management of HIV-1 infection","volume":"3","author":"NL Okeke","year":"2011","journal-title":"HIV\/AIDS\u2014Res Palliat Care"},{"issue":"3","key":"pone.0223464.ref005","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/mol.64.3.600","article-title":"Metal-dependent inhibition of HIV-1 integrase by \u03b2-diketo acids and resistance of the soluble double-mutant (F185K\/C280S)","volume":"64","author":"C Marchand","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"4","key":"pone.0223464.ref006","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/13543784.2011.562189","article-title":"GSK1349572, a new integrase inhibitor for the treatment of HIV: Promises and challenges","volume":"20","author":"JCC Lenz","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"pone.0223464.ref007","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1021\/jm400674a","article-title":"Inhibiting the HIV integration process: Past, present, and the future","volume":"57","author":"R Di Santo","year":"2014","journal-title":"J Med Chem"},{"issue":"1","key":"pone.0223464.ref008","first-page":"1","article-title":"Analyses of HIV-1 integrase sequences prior to South African national HIV-Treatment program and available of integrase inhibitors in Cape Town, South Africa","volume":"8","author":"D Brado","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0223464.ref009","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0b013e3181e9a87a","article-title":"Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness","volume":"55","author":"Z Hu","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"pone.0223464.ref010","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"JL Blanco","year":"2011","journal-title":"J Infect Dis"},{"issue":"6","key":"pone.0223464.ref011","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1128\/AAC.06170-11","article-title":"Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens","volume":"56","author":"C Garrido","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pone.0223464.ref012","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"M Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"9893","key":"pone.0223464.ref013","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"P Cahn","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"pone.0223464.ref014","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"T Doyle","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"pone.0223464.ref015","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1128\/AAC.04844-14","article-title":"Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro","volume":"59","author":"T Seki","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0223464.ref016","first-page":"1","volume-title":"Virus Research","author":"BG Brenner","year":"2017"},{"issue":"6","key":"pone.0223464.ref017","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.02568-12","article-title":"Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness","volume":"57","author":"ME Abram","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0223464.ref018","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/trf.14959","article-title":"Assessment of HIV transfusion transmission risk in South Africa: a 10-year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes","volume":"59","author":"M Vermeulen","year":"2019","journal-title":"Transfusion"},{"issue":"12","key":"pone.0223464.ref019","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/ci400537n","article-title":"Impact of Resistance Mutations on Inhibitor Binding to HIV-1 Integrase","volume":"53","author":"Q Chen","year":"2013","journal-title":"J Chem Inf Model"},{"issue":"1","key":"pone.0223464.ref020","first-page":"36","article-title":"Molecular dynamics simulation studies of the wild type and E92Q\/N155H mutant of Elvitegravir-resistance HIV-1 integrase","volume":"7","author":"Q Chen","year":"2015","journal-title":"Interdiscip Sci Comput Life Sci"},{"issue":"4\u20135","key":"pone.0223464.ref021","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.drup.2010.05.001","article-title":"Resistance to HIV-1 integrase inhibitors: A structural perspective","volume":"13","author":"JF Mouscadet","year":"2010","journal-title":"Drug Resist Updat"},{"issue":"4","key":"pone.0223464.ref022","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/QAI.0000000000000613","article-title":"\u201cSeek, Test, Treat\u201d Lessons From Australia","volume":"69","author":"AL Wilkinson","year":"2015","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"9","key":"pone.0223464.ref023","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1086\/598502","article-title":"Effect of HIV\u20101 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy","volume":"48","author":"AM Geretti","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0223464.ref024","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/jac\/dkw071","article-title":"Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors","volume":"71","author":"BG Brenner","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"pone.0223464.ref025","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2352-3018(16)00023-0","article-title":"Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden","volume":"3","author":"A H\u00e4ggblom","year":"2016","journal-title":"Lancet HIV"},{"key":"pone.0223464.ref026","doi-asserted-by":"crossref","DOI":"10.1038\/srep38153","article-title":"Wide variation in susceptibility of transmitted\/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency","volume":"6","author":"KA Sutherland","year":"2016","journal-title":"Sci Rep"},{"issue":"6320","key":"pone.0223464.ref027","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.aah5163","article-title":"Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome","volume":"355","author":"DO Passos","year":"2017","journal-title":"Science (80-)"},{"issue":"5","key":"pone.0223464.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.00708-13","article-title":"Small genomes and sparse metabolisms of sediment-associated bacteria from four candidate phyla","volume":"4","author":"RS Kantor","year":"2013","journal-title":"MBio"},{"issue":"21","key":"pone.0223464.ref029","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","article-title":"Clustal W and Clustal X version 2.0","volume":"23","author":"MA Larkin","year":"2007","journal-title":"Bioinformatics"},{"issue":"9","key":"pone.0223464.ref030","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/pro.5560020916","article-title":"Verification of protein structures: Patterns of nonbonded atomic interactions","volume":"2","author":"C Colovos","year":"1993","journal-title":"Protein Sci"},{"key":"pone.0223464.ref031","first-page":"710","article-title":"2\u00bb\u00c9\u00f8\u00cd\u00b8\u00d0\u00d4\u03bc\u00c4 \u00a9 19 9 2 Nature Publishing Group","volume":"359","author":"C. T. Kresge","year":"1992","journal-title":"Nature"},{"issue":"11","key":"pone.0223464.ref032","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM-GUI: A web-based graphical user interface for CHARMM","volume":"29","author":"S Jo","year":"2008","journal-title":"J Comput Chem"},{"issue":"1","key":"pone.0223464.ref033","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM Simulations Using the CHARMM36 Additive Force Field","volume":"12","author":"J Lee","year":"2016","journal-title":"J Chem Theory Comput"},{"issue":"25","key":"pone.0223464.ref034","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jcc.23354","article-title":"CHARMM36 all-atom additive protein force field: Validation based on comparison to NMR data","volume":"34","author":"J Huang","year":"2013","journal-title":"J Comput Chem"},{"key":"pone.0223464.ref035","unstructured":"Spoel D Van Der. Gromacs Reference Manual v5.1. 2011;"},{"issue":"4","key":"pone.0223464.ref036","article-title":"Theory and Techniques 12","author":"VY Lunin","year":"2002","journal-title":"Binary Integer Programming and its Use for Envelope Determination Bulk Solvent Correction for Yet Unsolved Structures Search of the Optimal Strategy for Refinement of Atomic Models Metal Coordination Groups in Proteins: Some Comm"},{"key":"pone.0223464.ref037","doi-asserted-by":"crossref","first-page":"NA","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","author":"K Vanommeslaeghe","year":"2009","journal-title":"J Comput Chem"},{"issue":"1","key":"pone.0223464.ref038","doi-asserted-by":"crossref","first-page":"014101","DOI":"10.1063\/1.2408420","article-title":"Canonical sampling through velocity rescaling","volume":"126","author":"G Bussi","year":"2007","journal-title":"J Chem Phys"},{"issue":"8","key":"pone.0223464.ref039","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/ct3001359","article-title":"Assessment of Common Simulation Protocols for Simulations of Nanopores, Membrane Proteins, and Channels","volume":"8","author":"J Wong-ekkabut","year":"2012","journal-title":"J Chem Theory Comput"},{"issue":"2","key":"pone.0223464.ref040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/00268978400101201","article-title":"A molecular dynamics method for simulations in the canonical ensemble","volume":"52","author":"S Nos\u00e9","year":"1984","journal-title":"Mol Phys"},{"issue":"3","key":"pone.0223464.ref041","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: Equilibrium phase-space distributions","volume":"31","author":"WG Hoover","year":"1985","journal-title":"Phys Rev A"},{"issue":"8","key":"pone.0223464.ref042","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1063\/1.449071","article-title":"The Nose-Hoover thermostat","volume":"83","author":"DJ Evans","year":"1985","journal-title":"J Chem Phys"},{"issue":"12","key":"pone.0223464.ref043","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models","volume":"33","author":"PA Kollman","year":"2000","journal-title":"Acc Chem Res"},{"key":"pone.0223464.ref044","unstructured":"Wang J, Wang W, Kollman PA, Case DA. Antechamber, An Accessory Software Package For Molecular Mechanical Calculations Correspondence to. Journal of Chemical Information and Computer Sciences."},{"issue":"2","key":"pone.0223464.ref045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jsb.2013.07.008","article-title":"Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance","volume":"184","author":"TG Dewdney","year":"2013","journal-title":"J Struct Biol"},{"issue":"1","key":"pone.0223464.ref046","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1021\/ci300541c","article-title":"Exploring the Molecular Mechanism of Cross-Resistance to HIV-1 Integrase Strand Transfer Inhibitors by Molecular Dynamics Simulation and Residue Interaction Network Analysis","volume":"53","author":"W Xue","year":"2013","journal-title":"J Chem Inf Model"},{"issue":"1","key":"pone.0223464.ref047","first-page":"2","article-title":"Molecular dynamics simulations: from structure function relationships to drug discovery","volume":"2","author":"PC Nair","year":"2014","journal-title":"Silico Pharmacol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0234581","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0223464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T13:29:43Z","timestamp":1588858183000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0223464"}},"subtitle":[],"editor":[{"given":"Peter J.","family":"Bond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,7]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0223464","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/781120","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,7]]}}}